IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Q-Line Biotech IPO is a Book Building listing on NSE EMERGE exchange, with an ipo size of ₹ [●] Cr. The company is based in Lucknow and caters to Healthcare sector. Hem Securities , Share India Capital Services are the merchant bankers of Q-Line Biotech IPO. It is a SME Upcoming IPO which filed its Draft Red Herring Prospectus (DRHP) on 30th September 2025.
Q-Line Biotech IPO posted revenues of ₹ 313.78 Cr. and PAT of ₹ 28.13 Cr. in FY25 on annualised basis.
Revenue:
₹ 313.78 Cr.
EBITDA Margin:
21.10
% 
Net Worth: ₹ 189.94 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: 1.78 times
Financial results of Q-Line Biotech IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | FY25 | FY24 | FY23 | ||
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 455.48 | 339.24 | 251.57 | ||
| Net Worth | 189.94 | 161.81 | 127.36 | ||
| Total Debt | 164.94 | 96.90 | 73.64 | ||
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
313.78 | 203.64 | 182.73 | ||
EBITDA
EBITDA on annualised basis |
66.21 | 40.79 | 35.76 | ||
PAT
PAT on annualised basis |
28.13 | 34.44 | 32.09 | ||
Q-Line Biotech IPO PAT Margin is 8.96 % , ROCE (Return on Capital Employed) is 23.74 % as per latest financial. The below table shows Q-Line Biotech IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | FY25 | FY24 | FY23 |
|---|---|---|---|
| EBITDA Margin (%) | 21.10 | 20.03 | 19.57 |
| PAT Margin (%) | 8.96 | 16.91 | 17.56 |
| EPS (₹) | 28.63 | 21.87 | 20.38 |
| ROE (%) | 14.81 | 21.28 | 25.20 |
| ROCE (%) | 23.74 | 21.29 | 25.20 |
| ROA (%) | 6.18 | 10.15 | 12.76 |
| Debt to Equity | 0.87 | 0.60 | 0.58 |
The market Capitalisation of Q-Line Biotech IPO is ₹ [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Q-Line Biotech IPO prospectus highlights an Return on Equity (ROE) of 14.81 % , Return on Assets (ROA) of 6.18 %, and an EBITDA Margin of 21.10 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Q-Line Biotech IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Q-Line Biotech IPO is ₹ [●] Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Q-Line Biotech IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Q-Line Biotech IPO reported revenue of ₹ 313.78 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Q-Line Biotech IPO provide insights into sales growth, market demand, and business scalability.
Q-Line Biotech recorded an EBITDA of ₹ 66.21 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Q-Line Biotech Profit After Tax (PAT) is ₹ 28.13 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 313.78 Cr.
EBITDA Margin:
21.10
%
Net Worth: ₹ 189.94 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA:
[●]
Q-Line Biotech operates in Healthcare and Engaged In The Business Of Developing, Manufacturing And Marketing Of Diverse Range Of Reagents. The Issue is listed on NSE EMERGE in Oct, 2025. Q-Line Biotech IPO size was with Issue price of .
Merchant Banker(s) of Q-Line Biotech IPO: Hem Securities Limited , Share India Capital Services Private Limited
Q-Line Biotech IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Q-Line Biotech IPO listed at a listing price of against the offer price of .
The current market price of Q-Line Biotech is .
Why Us?
